Barclays’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$5.96M Buy
425,981
+185,333
+77% +$2.59M ﹤0.01% 1494
2025
Q1
$3.27M Sell
240,648
-37,419
-13% -$508K ﹤0.01% 1709
2024
Q4
$5.67M Buy
278,067
+22,184
+9% +$452K ﹤0.01% 1491
2024
Q3
$7.45M Buy
255,883
+128,823
+101% +$3.75M ﹤0.01% 1214
2024
Q2
$2.95M Sell
127,060
-24,500
-16% -$569K ﹤0.01% 1448
2024
Q1
$3.11M Sell
151,560
-172,459
-53% -$3.54M ﹤0.01% 1638
2023
Q4
$6.95M Buy
324,019
+157,512
+95% +$3.38M ﹤0.01% 1273
2023
Q3
$3.44M Buy
166,507
+8,045
+5% +$166K ﹤0.01% 1346
2023
Q2
$4.68M Sell
158,462
-497,965
-76% -$14.7M ﹤0.01% 1261
2023
Q1
$15.1M Buy
656,427
+70,462
+12% +$1.62M 0.01% 681
2022
Q4
$16.3M Buy
585,965
+260,498
+80% +$7.24M 0.01% 701
2022
Q3
$9.99M Sell
325,467
-43,304
-12% -$1.33M 0.01% 817
2022
Q2
$10.9M Buy
368,771
+310,639
+534% +$9.14M 0.01% 793
2022
Q1
$1.87M Sell
58,132
-62,689
-52% -$2.02M ﹤0.01% 1824
2021
Q4
$5.39M Buy
120,821
+49,856
+70% +$2.22M ﹤0.01% 1191
2021
Q3
$3.58M Buy
70,965
+47,204
+199% +$2.38M ﹤0.01% 1442
2021
Q2
$1.87M Sell
23,761
-66,012
-74% -$5.18M ﹤0.01% 1763
2021
Q1
$5.13M Buy
89,773
+67,315
+300% +$3.84M ﹤0.01% 1173
2020
Q4
$1.88M Sell
22,458
-6,356
-22% -$533K ﹤0.01% 1605
2020
Q3
$1.03M Sell
28,814
-6,775
-19% -$243K ﹤0.01% 1905
2020
Q2
$860K Buy
35,589
+17,619
+98% +$426K ﹤0.01% 2009
2020
Q1
$314K Sell
17,970
-30,698
-63% -$536K ﹤0.01% 2354
2019
Q4
$848K Buy
48,668
+4,218
+9% +$73.5K ﹤0.01% 2404
2019
Q3
$681K Buy
44,450
+13,538
+44% +$207K ﹤0.01% 2456
2019
Q2
$642K Buy
30,912
+17,184
+125% +$357K ﹤0.01% 2589
2019
Q1
$319K Buy
+13,728
New +$319K ﹤0.01% 2823
2018
Q4
Sell
-17,071
Closed -$371K 4152
2018
Q3
$371K Buy
17,071
+15,833
+1,279% +$344K ﹤0.01% 2775
2018
Q2
$19K Sell
1,238
-2,099
-63% -$32.2K ﹤0.01% 3662
2018
Q1
$65K Buy
+3,337
New +$65K ﹤0.01% 3366